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During its October 2013 meeting, the Advisory Committee 
on Immunization Practices (ACIP) recommended use of a 
third meningococcal conjugate vaccine, MenACWY-CRM 
(Menveo, Novartis), as an additional option for vaccinating 
infants aged 2 through 23 months at increased risk for menin-
gococcal disease. MenACWY-CRM is the first quadrivalent 
meningococcal conjugate vaccine licensed for use in children 
aged 2 through 8 months. MenACWY-D (Menactra, Sanofi 
Pasteur) is recommended for use in children aged 9 through 
23 months who are at increased risk for meningococcal disease 
(1), and Hib-MenCY-TT (MenHibrix, GlaxoSmithKline) 
is recommended for use in children aged 6 weeks through 
18 months at increased risk (Table) (2). This report summarizes 
information on MenACWY-CRM administration in infants 
and provides recommendations for vaccine use in infants aged 
2 through 23 months who are at increased risk for meningococ-
cal disease (3). Because the burden of meningococcal disease 
in infants is low in the United States and the majority of cases 
that do occur are caused by serogroup B, which is not included 
in any vaccine licensed in the United States, only those infants 
who are at increased risk for meningococcal disease are recom-
mended to receive a meningococcal vaccine.
Methods
In monthly teleconferences, the ACIP Meningococcal 
Vaccines Work Group reviewed safety and immunogenicity 
data from five phase 3 clinical trials of MenACWY-CRM 
use in infants aged 2 through 23 months (4–8). Data on 
the concomitant administration of MenACWY-CRM and 
7-valent pneumococcal conjugate vaccine (PCV7) were dis-
cussed by both the Meningococcal and Pneumococcal ACIP 
work groups. The Meningococcal Vaccines Work Group also 
reviewed published peer-reviewed literature and unpublished 
data on disease epidemiology. Evidence of benefits, harms, 
values and preferences, and cost-effectiveness were reviewed in 
accordance with GRADE methods (9). A summary of the data 
reviewed and work group discussions were presented to ACIP, 
and recommendations for use of MenACWY-CRM in infants 
were approved by ACIP at its October 23–24, 2013 meeting.
Summary of Data Reviewed
MenACWY-CRM is a conjugate vaccine in which the cap-
sular polysaccharides from Neisseria meningitidis serogroups A, 
C, W, and Y are conjugated to the diphtheria toxin mutant 
CRM197 (10). The vaccine provides protection against 
meningococcal serogroups A, C, W, and Y, but not against 
serogroup B.
Immunogenicity of MenACWY-CRM in infants aged 2 
through 23 months was evaluated in four clinical trials (4–7). 
In all trials, enrolled subjects were randomized to receive either 
routine infant vaccinations and MenACWY-CRM, or routine 
infant vaccines alone. Human serum bactericidal antibody 
(hSBA) titers were used as a correlate of protection to assess 
vaccine immunogenicity; hSBA titers ≥1:8 were considered 
protective (4,7). Two open-label, multicenter trials assessed 
immunogenicity of a 4-dose MenACWY-CRM series, with 
doses at ages 2, 4, 6, and 12 months (4,7). A third trial assessed 
immunogenicity of a 4-dose series, with doses at ages 2, 4, 6, 
and 16 months, and a 3-dose series, with doses at ages 2, 6, 
and 12 months (6). A fourth randomized, open-label, multi-
center trial assessed immunogenicity of a 2-dose MenACWY-
CRM regimen, with doses at ages 7 through 9 months and 
12 months (5). In the first three trials, hSBA titers were assessed 
1 month after completion of the infant series (age 7 months) 
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and 1 month after completion of the full series (age 13 or 
17 months, depending on the dose regimen used) (4,6,7). 
In the fourth trial, hSBA titers were assessed 1 month after 
completion of the 2-dose series, at age 13 months.
In the first three trials, 1 month after completion of a 3-dose 
infant series, 67%–89% of subjects had protective hSBA titers 
for serogroup A, and 94%–98% had protective hSBA titers for 
serogroups C, W, and Y (4,6,7). In the first two trials, at age 
13 months, 89%–94% of infants achieved protective hSBA 
antibody titers for serogroup A, and 95%–100% achieved 
protective hSBA antibody titers for the remaining serogroups 
(4,7); similar immune responses were observed at ages 13 and 
17 months, respectively, among infants who received a 2-dose 
series (age 7 through 9 and 12 months) in the fourth trial or a 
3-dose infant series with a 16-month toddler dose (5,6,11) in 
the third trial. Among infants receiving doses at ages 2, 6, and 
12 months, 74% had protective hSBA titers for serogroup A, 
and at least 94% had protective hSBA titers for serogroups C, W, 
and Y at age 7 months; at least 94% had protective hSBA titers 
against all four serogroups at age 13 months (6). Preliminary 
results suggest that 2 years after a 4-dose MenACWY-CRM 
series (at ages 2, 4, 6, and 12 months) is completed, 34%–76% 
of children maintain protective hSBA titers for serogroups C, 
Y, and/or W (Novartis, unpublished data, 2013). However, 
protection against serogroup A wanes in almost all children by 
this time (Novartis, unpublished data, 2013).
Three trials evaluated concomitant administration of 
MenACWY-CRM and routine childhood vaccinations. 
Interference with immune responses to pneumococcal serotypes 
6B (4,7) and 23F (4) was suggested after PCV7 coadministra-
tion with the 3-dose infant series of MenACWY-CRM com-
pared with infants receiving PCV7 alone in two trials (4,7,11). 
However, after concomitant administration of PCV7 and the 
12-month dose of MenACWY-CRM, no reduction in responses 
to pneumococcal serotype 6B or 23F was observed (4,7,11).
No interference with the immune response was observed 
for pertussis antigens based on geometric mean concentra-
tion ratios (4–7). Seroresponses to other pneumococcal 
serotypes and to antigens in other routine childhood vac-
cines (diphtheria-tetanus-acellular pertussis-inactivated 
poliovirus-Haemophilus influenzae type b combined vaccine 
[DTaP-IPV-Hib] [Pentacel, Sanofi Pasteur]); hepatitis B virus 
TABLE. Summary of recommendations for meningococcal vaccination of children aged 2–23 months at increased risk for meningococcal 
disease — Advisory Committee on Immunization Practices, 2013
Vaccine
Age of primary 
vaccination Booster doses* Indicated for infants who: Not indicated for:
MenACWY-CRM 
(Menveo)
2, 4, 6, and 12 months •	1st booster 3 years after primary series •	Have complement component deficiencies
•	Additional boosters every 5 years •	Have functional or anatomic asplenia 
(including sickle cell disease)
•	Are in the risk group for an outbreak for which 
vaccination is recommended
•	Are traveling to or residing in regions where 
meningitis is epidemic or hyperendemic
MenACWY-D 
(Menactra)
9 and 12 months† •	1st booster 3 years after primary series •	Have complement component deficiencies •	Infants with functional 
or anatomic asplenia 
(including sickle cell 
disease)§
•	Additional boosters every 5 years •	Are in the risk group for an outbreak for which 
vaccination is recommended
•	Are traveling to or residing in regions where 
meningitis is epidemic or hyperendemic
Hib-MenCY-TT 
(MenHibrix)
2, 4, 6, and 12–15 
months
•	1st booster (using MenACWY-CRM or 
MenACWY-D¶) 3 years after primary series
•	Have complement component deficiencies •	Infants traveling 
internationally 
to regions where 
meningitis is epidemic 
or hyperendemic
•	Additional boosters (using MenACWY-CRM 
or MenACWY-D¶) every 5 years
•	Have functional or anatomic asplenia 
(including sickle cell disease)
•	Booster dose in children 
aged >18 months
•	Are in the risk group for an outbreak for which 
vaccination is recommended
* If the most recent dose was received before age 7 years, a booster dose should be administered 3 years later. 
† For infants aged 9–23 months, 2 doses of MenACWY-D should be administered 12 weeks apart. For infants receiving the vaccine before travel, the second dose may 
be administered as soon as 8 weeks after the first dose (additional information at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm).
§ Because of high risk for invasive pneumococcal disease, children with functional or anatomic asplenia should not be immunized with MenACWY-D before age 2 
years to prevent immune interference with 13-valent pneumococcal conjugate vaccine (PCV13).
¶ Hib-MenCY-TT should not be used for booster doses. A quadrivalent meningococcal vaccine (MenACWY-CRM or MenACWY-D) should be used for booster doses.
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vaccine; measles, mumps, and rubella vaccine; and measles, 
mumps, rubella, and varicella vaccine were not affected by 
MenACWY-CRM administration (4,5,11).
The work group also examined data from the five 
clinical trials evaluating adverse events in infants receiving 
MenACWY-CRM (4–8,11). Among approximately 5,000 sub-
jects studied through 6-months postvaccination, local and sys-
temic adverse events after administration of MenACWY-CRM 
and routine vaccinations were similar to those observed after 
routine vaccination alone (4–8,11); 11 serious adverse events 
were considered possibly related to MenACWY-CRM.* No 
deaths were considered related to MenACWY-CRM.
Recommendations
Vaccination with an age- and formulation-appropriate 
meningococcal conjugate vaccine is recommended for infants 
aged 2 through 23 months at increased risk for meningococcal 
disease. As described previously (1–3), infants at increased risk 
for meningococcal disease are:
•	 those with persistent complement component deficiencies 
(C3, C5–C9, properdin, factor D, and factor H),
•	 those with functional or anatomic asplenia (including 
sickle cell disease),
•	 healthy infants in communities with a meningococcal disease 
outbreak for which vaccination is recommended, and
•	 those traveling to or residing in areas where meningococcal 
disease is hyperendemic or epidemic.
Routine vaccination against meningococcal disease is not 
recommended for children aged 2 months through 10 years.
MenACWY-CRM may be used for protection against sero-
groups A, C, W, and Y in infants aged 2 through 23 months 
who are recommended for meningococcal vaccination because 
of an increased risk for meningococcal disease (Table). Infants 
are recommended to receive a 4-dose vaccination series, with 
doses at ages 2, 4, 6, and 12 months. Children initiating vac-
cination at ages 7 through 23 months are recommended to 
receive 2 doses of MenACWY-CRM, with the second dose 
administered at age ≥12 months and ≥3 months after the first 
dose. MenACWY-CRM is the only vaccine licensed for infants 
aged <9 months that includes protection against meningococ-
cal serogroups A and W; therefore, infants aged <9 months 
traveling to or residing in areas with hyperendemic or epidemic 
meningococcal disease caused by these serogroups should 
receive MenACWY-CRM before travel. Hib-MenCY-TT does 
not provide protection against serogroups A and W and should 
not be used for protection in infants traveling to or residing in 
areas with hyperendemic or epidemic meningococcal disease. 
Recommendations for use of the other infant meningococ-
cal vaccines, MenACWY-D and Hib-MenCY-TT, have been 
published previously and remain unchanged (Table) (1–3).
Because of differences in serogroup composition and licen-
sure indication, the same vaccine product should be used for 
all doses in infants at increased risk for meningococcal disease. 
However, if the product used for prior doses is unknown or 
unavailable, the vaccination series can be completed with any 
age- and formulation-appropriate meningococcal vaccine. 
Although no data are available on interchangeability of menin-
gococcal vaccines in infants, limited data from a postlicensure 
study in adolescents suggests safety and immunogenicity of 
MenACWY-CRM are not adversely affected by prior immu-
nization with MenACWY-D (12).
In previous recommendations, children with functional 
or anatomic asplenia (including sickle cell disease) were 
recommended to receive 13-valent pneumococcal conjugate 
vaccine (PCV13) according to the normal schedule but to 
delay MenACWY-D vaccination until age 2 years because of 
immune interference (1,3). Because MenACWY-CRM does 
not demonstrate immune interference with PCV7 after the 
12-month dose, it can be administered concomitantly with 
PCV13. ACIP recommends that infants aged 2 through 
23 months with functional or anatomic asplenia either receive 
MenACWY-CRM or Hib-MenCY-TT or wait until age 2 years 
to receive MenACWY-D (Table).
For children at prolonged increased risk for meningococ-
cal disease, ACIP recommends booster doses of conjugate 
meningococcal vaccine after completion of the primary series. 
As stated previously (1), if the most recent dose was received 
before age 7 years, a booster dose should be administered 
3 years later. Additional boosters should be administered every 
5 years thereafter.
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